Top Stocks to Trade Now: AI Pivots, FDA Fast Tracks, and Breakout Setups Driving Momentum
DENVER, Colo., Jul 29, 2025 (247marketnews.com)- Markets are showing renewed strength across biotech, AI security, and speculative growth names.
SoFi Technologies, Inc. (NASDAQ:SOFI) is on every growth trader’s radar after reporting Q2 earnings and raising its 2025 guidance. The fintech firm continues expanding across digital banking, lending, and financial services at scale. Strong net interest income and user growth are fueling the upside.
ScanTech AI (NASDAQ:STAI) just announced a Letter of Intent with Visiontec Systems for the purchase of multiple SENTINEL Fixed Gantry CT inspection systems, slated for use at one of the world’s largest nuclear facilities.
“We believe that this follow-on commitment from Visiontec reflects accelerating market adoption,” said CEO Dolan Falconer.
The LOI builds on a $3.5 million engagement and signals early 2025 revenue momentum as ScanTech expands its footprint in mission-critical infrastructure and nuclear energy security—a high-growth, high-barrier segment with geopolitical relevance.
Venu (NYSE:VENU) has now logged ten consecutive green days and is hovering just below a major technical breakout level. With its Reg A Preferred Offering officially closed, a key overhang has lifted, paving the way for momentum traders to push the stock toward $22.30, the target set by Cenorium.
CEO J.W. Roth recently invested $5M personally, with plans to increase to $20M, highlighting internal conviction, as VENU is on pace to deliver $100M annually from its NNN FireSuites, which offer 11% cap rates and zero exposure to taxes, insurance, or maintenance. Add to that a $200M traditional Luxe FireSuites goal and a $5B development pipeline, and VENU becomes one of the most talked-about live entertainment and income REIT-style plays.
Sarepta Therapeutics (NASDAQ:SRPT) received a boost after J.P. Morgan upgraded the stock to Neutral, citing the FDA’s decision to lift the clinical hold on its Elevidys gene therapy program. This decision reopens a significant commercial pathway for Sarepta in Duchenne muscular dystrophy (DMD), a high-value rare disease market.
The FDA greenlight removes a major overhang and injects renewed institutional confidence. Watch for volume surges and potential technical follow-through.
Calidi Biotherapeutics (NYSE:CLDI) received FDA Fast Track designation for CLD-201 (SuperNova), its stem-cell-delivered oncolytic virus therapy aimed at soft tissue sarcoma. This opens the door to accelerated FDA interaction and potential priority review.
“We believe CLD-201 has the potential to provide durable and transformational treatment,” said Chief Medical Officer Guy Travis Clifton, M.D.
Siyata Mobile (NASDAQ:SYTA) is transforming from a rugged mobile device manufacturer into a next-gen AI content player through a $185 million merger with Core Gaming, which boasts 43 million monthly active users.
If approved by Nasdaq, the combined entity is targeting $100M in 2025 revenue with a focus on AI-powered entertainment. This type of pivot is drawing both momentum traders and long-term investors, especially as the AI/gaming crossover theme heats up. Regulatory approval remains the final hurdle for this speculative but transformational story.
Scinai Immunotherapeutics (NASDAQ:SCNI) is gaining traction after announcing that its monoclonal antibody candidate PC111 was featured in the Journal of Dermatological Treatment, highlighting its disease-modifying potential in dermatologic inflammation.
As a boutique biopharma/CDMO hybrid targeting unmet needs in immunology, Scinai’s validation from peer-reviewed research signals a meaningful step in derisking its pipeline—and attracting speculative capital.
DURECT (NASDAQ:DRRX) jumped after announcing a definitive acquisition agreement with Bausch Health Companies (NYSE:BHC). The deal gives Bausch access to larsucosterol, a promising epigenetic modulator showing efficacy in alcoholic hepatitis (AH) during Phase 2 trials.
This marks one of the more strategic biotech buyouts of 2025 and puts Bausch on the map in the fast-emerging epigenetics space.
fuboTV (NYSE:FUBO) shares climbed after issuing higher Q2 revenue guidance, reigniting interest in the company’s live TV streaming bundle with a sports-first strategy. With the sports streaming wars heating up, Fubo stands out as a potential acquisition target and disruptive niche player.
Antelope (NASDAQ:AEHL) jumped after disclosing an SPA with Streeterville Capital for up to $50 million in financing, 100% earmarked for Bitcoin purchases. This move marks AEHL’s shift from planning to execution in crypto asset accumulation, making it a speculative favorite in the small-cap blockchain space.
Amkor (NASDAQ:AMKR) posted Q2 GAAP EPS of $0.22, beating by $0.06, and revenue of $1.51B, surpassing expectations by $90 million. As a leader in semiconductor packaging and test services, Amkor is directly tied to the ongoing AI hardware boom, making it a top pick for investors seeking exposure beyond NVIDIA.
Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.
For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/ or https://247marketnews.com/venu-disclosure/ for additional VENU disclosure.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com